SLC5A2 and cardiovascular disorder: The final major SGLT2 inhibitor clinical trial is the Evaluation of Ertugliflozin efficacy and Safety Cardiovascular Outcomes (VERTIS) study [53], where the effect of Ertugliflozin in patients with both T2D and Cardiovascular Disease was investigated.